These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3492613)

  • 1. Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report.
    Merguerian PA; Donahue L; Cockett AT
    J Urol; 1987 Feb; 137(2):216-9. PubMed ID: 3492613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guerin and interleukin-2 for treatment of superficial bladder cancer.
    Cockett AT; Davis RS; Cos LR; Wheeless LL
    J Urol; 1991 Sep; 146(3):766-9; discussion 769-70. PubMed ID: 1875490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guerin and interleukin-2 immunotherapy.
    Sosnowski JT; De Haven JI; Abraham FM; Riggs DR; Lamm DL
    J Urol; 1992 May; 147(5):1439-43. PubMed ID: 1569700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
    Brosman SA
    J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by postoperative urinary cytology.
    Badalament RA; Gay H; Cibas ES; Herr HW; Whitmore WF; Fair WR; Melamed MR
    J Urol; 1987 Oct; 138(4):763-5. PubMed ID: 3656528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin.
    Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR
    J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder cancer immunotherapy.
    Lamm DL; Thor DE; Stogdill VD; Radwin HM
    J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.
    Hillyard RW; Ladaga L; Schellhammer PF
    J Urol; 1988 Feb; 139(2):290-3. PubMed ID: 3339727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer.
    Lage JM; Bauer WC; Kelley DR; Ratliff TL; Catalona WJ
    J Urol; 1986 May; 135(5):916-9. PubMed ID: 3959240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
    Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
    J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder.
    Pansadoro V; De Paula F
    J Urol; 1987 Aug; 138(2):299-301. PubMed ID: 3599242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
    Schellhammer PF; Ladaga LE; Fillion MB
    J Urol; 1986 Feb; 135(2):261-4. PubMed ID: 3511283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.